Qiagen (NASDAQ: QGEN) reported Q4 EPS of $0.39, $0.05 better than the analyst estimate of $0.34. Revenue for the quarter came in at $366.5 million versus the consensus estimate of $370.69 million.

"QIAGEN's performance during 2016 shows our transformation is building momentum thanks to the power of our Sample to Insight portfolio and we are moving ahead on a new growth trajectory," said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. "We have strengthened our position as a global leader in molecular testing, and we expect to make significant progress in 2017."

For earnings history and earnings-related data on Qiagen (QGEN) click here.